2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1144

Understanding Clinical Trials Participation Among Individuals of African Descent with Lupus Through the Lens of Critical Race Theory: A Qualitative Analysis
Abstract Number: 2083

Understanding Knee Function and Symptom Management in Individuals with Risk Factors for Knee Osteoarthritis
Abstract Number: 2037

Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity
Abstract Number: 568

Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility
Abstract Number: 367

Understanding the Mystery of Sarcoidosis: An Academic Rheumatology Center Experience
Abstract Number: 2251

Understanding Vulnerabilities in Diagnosis and Care of Childhood and Adult-Onset Lupus: A Qualitative Study
Abstract Number: 435

Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower
Abstract Number: 18

Undifferentiated Connective Tissue Disease at Risk for SSc: Potential Role of Circulating CXCL-10, CXCL-11 and IL-33 in Predicting Disease Evolution
Abstract Number: 79

Unique Primed Status of Microglia Under the Systemic Autoimmune Condition of Lupus-Prone Mice
Abstract Number: 1332

United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization
Abstract Number: 2479

Unmet Treatment Needs in Patients with Psoriatic Arthritis
Abstract Number: 513

Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Abstract Number: 518

Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
Abstract Number: 551

Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis
Abstract Number: 1219

Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].